Guarantee Complex Model Validation, Secure Regulatory Support & Advance Clinical Translation

Partner in 2027

Tackling Complex In Vitro Model Validation, Balancing Scalability with Reproducibility & Cost to Ensure Translational Success Across Drug Discovery & Development

Regulatory and governmental momentum is forcing change, fast:

The Senate have recently cleared the FDA Modernization Act 3.0
The FDA have developed a roadmap that’s abandoning animal testing for mAbs
NIH have closed the door on animal-only grants
The UK join the plan to phase out animal testing, announced by the Science Minster Lord Vallance

Meanwhile, your pipelines are chasing novel targets that in vivo models can't predict.

The 11th 3D Tissue Models Summit is where the industry came to solve this. As the only industry-led forum dedicated to advancing organoids, organ-on-chip, and MPS, attanedees connected with experts from AbbVie, Novartis, Vertex, and many more to discuss model validation with regulators, and making them work at scale.

View The 2026 Agenda

New modalities are moving towards NAMs. I’m attending to see how others employ in vitro models to deliver medicines faster and safer to patients.

Malini Iyer, Associate Director, Oncology Safety Sciences, AstraZeneca
It's valuable to have a place where people interested in advanced 3D models come together. We can share knowledge, learn from each other's challenges, and work together to advance the field.

Bindu Sukumaran, Senior Principal Scientist, Novartis
I'm attending because 3D tissue model development thrives on sharing rather than competing. The more we collaborate on these systems, the better for everyone.

Regis Doyonnas, Senior Principal Scientist & Associate Fellow-Research, Pfizer